These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 14534718)

  • 21. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.
    van Imhoff GW; McMillan A; Matasar MJ; Radford J; Ardeshna KM; Kuliczkowski K; Kim W; Hong X; Goerloev JS; Davies A; Barrigón MDC; Ogura M; Leppä S; Fennessy M; Liao Q; van der Holt B; Lisby S; Hagenbeek A
    J Clin Oncol; 2017 Feb; 35(5):544-551. PubMed ID: 28029326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ifosfamide, epirubicin and etoposide rituximab in refractory or relapsed B-cell lymphoma: analysis of remission induction and stem cell mobilization.
    Menzel H; Müller A; Von Schilling C; Licht T; Peschel C; Keller U
    Leuk Lymphoma; 2008 Jul; 49(7):1337-44. PubMed ID: 18604723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rituximab provides durable remission in a patient with refractory aggressive diffuse B-cell lymphoma failing salvage chemotherapy.
    Robach E; Ustun C; Kallab A; Burgess RE; Jillella AP
    Leuk Lymphoma; 2002 Nov; 43(11):2235-6. PubMed ID: 12533055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I-II study of rituximab, ifosfamide, mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT).
    Joyce RM; Regan M; Ottaway J; Umiel T; Tetreault JC; Levine J; McDermott D; Hurley D; Giallombardo N; Smith T; Lamontagne D; Uhl L; Avigan D
    Ann Oncol; 2003; 14 Suppl 1():i21-7. PubMed ID: 12736227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma?
    Gisselbrecht C
    Hematology Am Soc Hematol Educ Program; 2012; 2012():410-6. PubMed ID: 23233612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma.
    Salar A; Martino R; Perea G; Ribera JM; López-Guillermo A; Guardia R; Escoda L; Altés A; Sierra J; Montserrat E
    Haematologica; 2002 Oct; 87(10):1028-35. PubMed ID: 12368156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study.
    Kirschey S; Flohr T; Wolf HH; Frickhofen N; Gramatzki M; Link H; Basara N; Peter N; Meyer RG; Schmitz N; Weidmann E; Banat A; Schulz A; Kolbe K; Derigs G; Theobald M; Hess G
    Br J Haematol; 2015 Mar; 168(6):824-34. PubMed ID: 25546611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
    Haq R; Sawka CA; Franssen E; Berinstein NL
    Leuk Lymphoma; 1999 Nov; 35(5-6):527-36. PubMed ID: 10609790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).
    Coleman M; Leonard J; Shuster MW; Kaufman TP
    Eur J Haematol Suppl; 2001 Jul; 64():41-5. PubMed ID: 11486401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma.
    Rigacci L; Fabbri A; Puccini B; Chitarrelli I; Chiappella A; Vitolo U; Levis A; Lauria F; Bosi A
    Cancer; 2010 Oct; 116(19):4573-9. PubMed ID: 20572029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of modified rituximab-ESHAP therapy for relapsed/refractory B-cell lymphoma.
    Ueda K; Nannya Y; Asai T; Yamamoto G; Hangaishi A; Takahashi T; Imai T; Kurokawa M
    J Chemother; 2010 Feb; 22(1):54-7. PubMed ID: 20227994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
    Weide R; Hess G; Köppler H; Heymanns J; Thomalla J; Aldaoud A; Losem C; Schmitz S; Haak U; Huber C; Unterhalt M; Hiddemann W; Dreyling M;
    Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Preliminary study on DHAP regimen for patients with relapsed and refractory non-Hodgkin's lymphoma].
    Li YH; Jiang WQ; Huang HQ; Zhang L; Liu DG; Xu RH; Zhou ZM; Sun XF; Lin TY; Xu GC; He YJ; Guang ZZ
    Ai Zheng; 2002 Aug; 21(8):900-2. PubMed ID: 12478903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative toxicities of 3 platinum-containing chemotherapy regimens in relapsed/refractory lymphoma patients.
    Tixier F; Ranchon F; Iltis A; Vantard N; Schwiertz V; Bachy E; Bouafia-Sauvy F; Sarkozy C; Tournamille JF; Gyan E; Salles G; Rioufol C
    Hematol Oncol; 2017 Dec; 35(4):584-590. PubMed ID: 27377614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group.
    Witzig TE; Geyer SM; Kurtin PJ; Colgan JP; Inwards DJ; Micallef IN; LaPlant BR; Michalak JC; Salim M; Dalton RJ; Moore DF; Reeder CB;
    Leuk Lymphoma; 2008 Jun; 49(6):1074-80. PubMed ID: 18569634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Efficacy and survival status of retuximab-NCE regimen treatment in patients with relapsed or refractory B cell non-Hodgkin's lymphoma].
    Hou Y; Wang HQ; Fu K; Liu XM; Zhang HL; Qian ZZ; Qiu LH; Li W; Zhou SY; Li LF; Hao XS
    Zhonghua Zhong Liu Za Zhi; 2012 Apr; 34(4):306-10. PubMed ID: 22781046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
    Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma.
    Sieniawski M; Staak O; Glossmann JP; Reineke T; Scheuss H; Diehl V; Engert A; Josting A
    Ann Hematol; 2007 Feb; 86(2):107-15. PubMed ID: 17103169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.